TY - JOUR
T1 - Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides
AU - Talpur, Rakhshandra
AU - Sui, Dawen
AU - Gangar, Pamela
AU - Dabaja, Bouthaina S.
AU - Duvic, Madeleine
N1 - Funding Information:
This research was supported by the National Cancer Institute (NCI) MDACC Core Grant CA16672-22, NCI (R21-CA74117), NIAMS K24 CA 86815, the Stanton Research Fellowship Fund, the Sherry L. Anderson Fund for CTCL Research, the CTCL Patient Education and Research Fund, the Drs Dorothy and Martin Spatz Foundation, and the Blanche Bender Professorship in Cancer Research (M.D.).
Funding Information:
This research was supported by the National Cancer Institute (NCI) MDACC Core Grant CA16672-22 , NCI ( R21-CA74117 ), NIAMS K24 CA 86815 , the Stanton Research Fellowship Fund, the Sherry L. Anderson Fund for CTCL Research, the CTCL Patient Education and Research Fund, the Drs Dorothy and Martin Spatz Foundation, and the Blanche Bender Professorship in Cancer Research (M.D.).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Introduction Large cell transformation (LCT) of mycosis fungoides (MF) is associated with an aggressive clinical course, poor overall survival (OS), and variable CD30 expression. Patients and Methods We retrospectively analyzed 1900 MF/Sézary syndrome patients' clinical, histologic and immunophenotype and identified 187 patients seen between 1982 and 2012. Results Most advanced stage patients with LCT were male 86 of 155 (55.4%) and 69 were female (44.5%). Incidence of LCT (n = 187) was 9.8% (187/1900) in skin and/or nodes of the entire MF/SS database population (n = 1900). Advanced stage patients represented 83% of patients whose median OS was 4.1 years (95% confidence interval [CI], 3.5-5.4). Early stage patients represented 17% with OS of 8.0 years. Among 187 LCT patients, 136 patients (73%) were diagnosed with LCT at the time of initial diagnosis of MF. Their median OS was 3.6 years (95% CI, 3.3-5.3). Of the 51 patients who had LCT diagnosed after their initial diagnosis of MF, their median OS was 8.8 years (P =.0001; 95% CI, 1.6-4.1). The OS for all LCT patients was 4.8 years, for patients older than 60 years of age OS was 3.7 years (95% CI, 2.7-5.4) and was 6.2 years (95% CI, 4.5-9.8) for patients younger than 60 years of age (P =.0001). An increased lactate dehydrogenase level was associated with a decreased OS (P =.03; hazard ratio, 1.5; 95% CI, 1.0-2.2). Patients with CD30 expression in ≥ 10% of the lymphocytes in skin biopsies were 40% more likely to survive than patients with low expression. Conclusion In summary, risk factors associated with disease progression were advanced age, LCT at the time of initial diagnosis of MF, high levels of lactate dehydrogenase, and CD30 expression < 10%.
AB - Introduction Large cell transformation (LCT) of mycosis fungoides (MF) is associated with an aggressive clinical course, poor overall survival (OS), and variable CD30 expression. Patients and Methods We retrospectively analyzed 1900 MF/Sézary syndrome patients' clinical, histologic and immunophenotype and identified 187 patients seen between 1982 and 2012. Results Most advanced stage patients with LCT were male 86 of 155 (55.4%) and 69 were female (44.5%). Incidence of LCT (n = 187) was 9.8% (187/1900) in skin and/or nodes of the entire MF/SS database population (n = 1900). Advanced stage patients represented 83% of patients whose median OS was 4.1 years (95% confidence interval [CI], 3.5-5.4). Early stage patients represented 17% with OS of 8.0 years. Among 187 LCT patients, 136 patients (73%) were diagnosed with LCT at the time of initial diagnosis of MF. Their median OS was 3.6 years (95% CI, 3.3-5.3). Of the 51 patients who had LCT diagnosed after their initial diagnosis of MF, their median OS was 8.8 years (P =.0001; 95% CI, 1.6-4.1). The OS for all LCT patients was 4.8 years, for patients older than 60 years of age OS was 3.7 years (95% CI, 2.7-5.4) and was 6.2 years (95% CI, 4.5-9.8) for patients younger than 60 years of age (P =.0001). An increased lactate dehydrogenase level was associated with a decreased OS (P =.03; hazard ratio, 1.5; 95% CI, 1.0-2.2). Patients with CD30 expression in ≥ 10% of the lymphocytes in skin biopsies were 40% more likely to survive than patients with low expression. Conclusion In summary, risk factors associated with disease progression were advanced age, LCT at the time of initial diagnosis of MF, high levels of lactate dehydrogenase, and CD30 expression < 10%.
KW - Anaplastic large T cell lymphoma
KW - CD30 cutaneous T-cell lymphoma
KW - CD30 lymphoproliferative disorders
KW - Cutaneous T cell lymphoma
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=84952871600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952871600&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.11.010
DO - 10.1016/j.clml.2015.11.010
M3 - Article
C2 - 26702474
AN - SCOPUS:84952871600
SN - 2152-2650
VL - 16
SP - 49
EP - 56
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 1
ER -